View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Suvoda WP
March 27, 2012updated 13 Jul 2022 11:14am

Clovis Oncology concludes patient enrollment in LEAP trial

Clovis Oncology has completed patient enrolment in its pivotal Low hENT1 and Adenocarcinoma of the Pancreas (LEAP) study of CO-101 versus gemcitabine in metastatic pancreatic cancer patients.

pancreatic cancer

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Clovis Oncology has completed patient enrolment in its pivotal Low hENT1 and Adenocarcinoma of the Pancreas (LEAP) study of CO-101 versus gemcitabine in metastatic pancreatic cancer patients.

CO-101, also known as CP-4126, is a patented, lipid-conjugated form of the anti-cancer drug gemcitabine, which was designed to enter cancer cells regardless of human Equilibrative Nucleoside Transporter 1 (hENT1) expression.

CO-101 is intended to address the unmet need of patients with pancreatic cancer whose tumours express low amounts of hENT1 and are therefore expected to be resistant to standard gemcitabine therapy.

LEAP is an international randomised controlled 360-patient pivotal trial, in which patients are being randomised on a one-to-one basis to receive either CO-101 or gemcitabine.

The study is being conducted at 99 centres in 15 countries to demonstrate that CO-101 improves overall survival compared to gemcitabine in hENT1-low metastatic pancreatic cancer patients.

Clovis Oncology president and CEO Patrick Mahaffy said the trial has the potential to be practice-changing in the management and treatment of metastatic pancreatic cancer for which only limited options are available.

LEAP is the first trial that seeks to prospectively demonstrate the correlation using a fully validated IHC assay, with a pre-defined ‘cut-off’ of hENT1-high and hENT1-low, the company said.

CO-101 has already received an orphan drug designation in the US and European Union for the treatment of pancreatic cancer.

The company plans to file for approval in the US and European Union by mid 2013, if the trial is successful.

Headquartered in Boulder, US, Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercialising innovative anti-cancer agents in the US, Europe and additional international markets.

 

Image: Micrograph of pancreatic ductal adenocarcinoma. Photo: KGH.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena